What happened with NNOX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Nano-X Imaging receives most of its revenue from arranging for radiologists to interpret medical images remotely through USARAD and Nanox.MARKETPLACE. Hospitals, healthcare providers and payors pay for these services. Revenue comes almost entirely from the United States, without a single dominant customer. This business depends on referrals and access to radiologists licensed and credentialed where they provide care; local medical-practice rules restrict how services can be delivered.
The company is also commercializing Nanox.ARC and Nanox.ARC X, which use its digital X-ray source to produce layered images of adult anatomy alongside conventional X-rays. Hospitals and imaging centers can buy systems outright or receive them at low or no upfront cost, with Nano-X taking a share of scan proceeds. It is increasingly emphasizing outright sales through distributors, including Howard Technology Solutions. Commercial deployment remains early: most deployed systems have not yet generated revenue, and the U.S. pipeline relies on a small group of partners. Turning deployments into revenue depends on site readiness, activation, scan use and required local permits. FDA clearance covers specified uses, but does not ensure insurance coverage or reimbursement.
Nanox AI also sells software that examines existing CT scans for signs of overlooked disease. Nanox Health IT resells and supports third-party healthcare technology, with plans to help deploy the AI software in U.S. healthcare organizations. These activities contribute much less revenue than remote radiology.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Nano-X’s commercialization hinges on imaging deployments that generate revenue, but most current revenue comes from remote radiology services, where it competes with StatRad, ONRAD and vRad.
Nano-X depends on Varex Imaging Corporation for Nanox.ARC X-ray tubes, paying it a share of worldwide scan revenue from systems using those tubes, with an annual minimum per system. Where local regulators allow, Nano-X must use Varex tubes in a minimum share of deployed, operating systems, making tube supply and scans on those systems worth watching together.
GE HealthCare competes with Nano-X for healthcare providers’ imaging-equipment budgets: both sell diagnostic imaging systems and related software. GE HealthCare’s Imaging segment is the part to watch for spending by hospitals and health systems, rather than its broader medical-device revenue.
Philips competes with Nano-X for healthcare providers’ diagnostic imaging spending, offering imaging systems, clinical software and tools for managing imaging information. Watch adoption of Philips’ combined imaging and software offerings in Diagnosis & Treatment, which it promotes through evidence of clinical and economic benefits.
Nano-X relies on Fabrinet to scale up Nanox.ARC X production, paying the contract manufacturer for assembly, testing, procurement and quality control under a multi-year agreement. Watch whether manufacturing costs are low enough to support Nano-X’s subscription model; being able to build the systems alone does not settle that question.
Fabrinet earningsFN
Fabrinet’s report will show whether the manufacturer assembling and testing Nano-X’s Nanox.ARC X systems can scale output at a cost that supports Nano-X’s per-scan subscription model.
Watch Fabrinet’s manufacturing business alongside whether Nano-X can control system costs as deployments grow. More output with costs contained would suggest outsourced production can support more systems earning scan fees; rising costs or limited capacity would make deployments harder to scale and increase Nano-X’s funding burden.
Varex Imaging Corporation earningsVREX
Varex Imaging’s report can show activity in systems using its X-ray tubes, which matters because Nano-X shares scan revenue from those systems with Varex.
Read Varex’s business alongside scan volume and related revenue from Nano-X systems using Varex tubes. More scans bring Nano-X more per-scan revenue but also raise its share paid to Varex; low scan activity limits revenue, while the annual minimum per system may still apply.
NANO-X IMAGING LTD earningsThis company
Nano-X earns most of its revenue from teleradiology, and this report will show whether imaging systems and AI are starting to add growth while cash use remains heavy.
Read revenue from teleradiology, Nanox.ARC systems and AI alongside cash used in operations. Rising system and AI revenue with lower cash use would show the newer businesses are beginning to supplement the core and could ease financing pressure; if revenue still comes mostly from teleradiology and operating cash use remains heavy, growth remains constrained by the core and the need for outside funding.
